Top

Journal of Autism and Developmental Disorders

Gepubliceerd in:

01-03-2013 | Brief Report

Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials

Auteurs: Lawrence Scahill, Victoria Hallett, Michael G. Aman, Christopher J. McDougle, L. Eugene Arnold, James T. McCracken, Elaine Tierney, Yanhong Deng, James Dziura, Benedetto Vitiello, the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network)

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 3/2013

Abstract

There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to placebo and 49 subjects to risperidone under double-blind conditions. Study 2 included 49 subjects assigned to risperidone only and 75 subjects assigned to risperidone plus parent training. After 8 weeks of treatment, all active treatments were superior to placebo (effect sizes ranging from 0.42 to 0.65). The findings suggest that the Social Withdrawal subscale may be a useful measure of social disability in acute treatment trials.

vorige artikel Brief Report: Structure of Personal Narratives of Adults with Autism Spectrum Disorder

volgende artikel Parents’ Perspectives on the Role of Pediatricians in Autism Diagnosis

Alleen toegankelijk voor geautoriseerde gebruikers

Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143–1154.PubMedCrossRef

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89, 492–502.PubMed

Autism Speaks. (2011). Autism speaks announces a major effort to develop new effective medical treatments for people with ASD. http://blog.autismspeaks.org/2011/02/15/science-effective-medical-treatments. Accessed September 18, 2012.

Brown, E. C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist—Community for young people in special education. Research in Developmental Disabilities, 23, 45–60.PubMedCrossRef

Carter, A. S., Volkmar, F. R., Sparrow, S. S., et al. (1998). The Vineland Adaptive Behavior Scales: Supplementary norms for individuals with autism. Journal of Autism and Developmental Disorders, 28(4), 287–302.PubMedCrossRef

Centers for Disease Control and Prevention. (2012). Prevalence of Autism Spectrum Disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. Morbidity Mortality Weekly Report, 61(3), 2–19.

Dolen, G., Carpenter, R. L., Ocain, T. D., & Bear, M. F. (2010). Mechanism-based approaches to treating fragile X. Pharmacology & Therapeutics, 127(2010), 78–93.CrossRef

Gadow, K. D., DeVincent, C., & Schneider, J. (2008). Predictors of psychiatric symptoms in children with an Autism Spectrum Disorder. Journal of Autism and Developmental Disorders, 38, 1710–1720.PubMedCrossRef

Guy, W. (1976). Clinical global impressions. In ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health.

Interagency Autism Coordinating Committee. (2011). IACC strategic plan for autism spectrum disorder research. Retrieved from the Department of Health and Human Services Interagency Autism Coordinating Committee website at http://iacc.hhs.gov/strategic-plan/2011/index.shtml (2011 Jan).

Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., et al. (2011). Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Science Translational Medicine, 3(64), 64ra1.PubMedCrossRef

King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behaviour: citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583–590.PubMedCrossRef

Lord, C., Rutter, M., & Le Couteur, A. (1994). Autism diagonostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders, 24, 659–685.PubMedCrossRef

Lecavalier, L. (2006). Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders, 36, 1101–1114.PubMedCrossRef

Levy, S. E., Mandell, D. S., & Schultz, R. T. (2007). Autism. Lancet, 374(9701), 1627–1638 (Erratum appears in Lancet. 2011 Oct 29;378(9802):1546).

Marcus, R. N., Owen, R., Kamen, L., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119.PubMedCrossRef

O’ Roak, B. J., & State, M. W. (2008). Autism genetics: Strategies, challenges, and opportunities. Autism Research, 1(1), 4–17.PubMedCrossRef

Owen, R., Sikich, L., Marcus, R., et al. (2009). A multicenter, double-blind, randomized, placebo controlled, flexible-dose, parallel-group study of aripiprazole in the treatment of irritability in children and adolescents (6–17 years) with autistic disorder. Pediatrics, 124, 1533–1540.PubMedCrossRef

Posey, D. J., Erickson, C. A., & McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child & Adolescent Psychiatric Clinics of North America, 17(4), 787–801.CrossRef

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274.

Robinson, E. B., Koenen, K. C., McCormick, M. C., Munir, K., Hallett, V., Happe, F., et al. (2011). Evidence that autistic traits show the same etiology in the general population and at the quantitative extremes (5%, 2.5%, and 1%). Archives of General Psychiatry, 68(11), 1113–1121.PubMedCrossRef

RUPP Autism Network. (2002). Risperidone in children with autism and serious behavioral problems. NEJM, 347(5), 314–321.CrossRef

Scahill, L., McDougle, C. J., Aman, M. G., Johnson, C., Handen, B., Bearss, K., et al. (2012). Effects of risperidone and parent training on adaptive functioning in children with a pervasive developmental disorders and serious behavioral problems. Journal of the American Academy of Child and Adolescent Psychiatry, 51(2), 136–146.PubMedCrossRef

Shea, S., Turgay, A., Carrol, A., et al. (2004). Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641.PubMedCrossRef

Sparrow, S. S., Balla, D. A., & Cicchetti, D. V. (1984). Vineland adaptive behavior scales. Circle Pines, MN: American Guidance Service.

Sukhodolsky, D. G., Scahill, L., Gadow, K. D., Arnold, L. E., Aman, M. G.., McDougle, C. J., et al. (2008). Parent-rated anxiety symptoms in children with pervasive developmental disorders: Frequency and association with core autism symptoms and cognitive functioning. Journal of Abnormal Child Psychology, 36(1), 117–128.PubMedCrossRef

US Food and Drug Administration. (2006). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. Available from: ttp://www.Fda.Gov/Cder/Guidance/5460dft.Pdf [Accessed May 4, 2007]. Federal Register: February 3, 2006, Vol. 71. Number (23) Docket no. 2006D-0044.

Veenstra-VanderWeele, J., King, B., Erickson, C., Ginsberg, L., Melman, R., Scahill, L., et al. (2011). An open label trial of arbaclofen in autism spectrum disorder shows improvements in multiple symptom domains. Poster presentation at NCDEU. Spring, 2011.

Titel: Brief Report: Social Disability in Autism Spectrum Disorder: Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials
Auteurs: Lawrence Scahill
Victoria Hallett
Michael G. Aman
Christopher J. McDougle
L. Eugene Arnold
James T. McCracken
Elaine Tierney
Yanhong Deng
James Dziura
Benedetto Vitiello
the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network)
Publicatiedatum: 01-03-2013
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders / Uitgave 3/2013
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-012-1689-3

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 3/2013

Parents’ Perspectives on the Role of Pediatricians in Autism Diagnosis

Broad Autism Phenotype in Typically Developing Children Predicts Performance on an Eye-Tracking Measure of Joint Attention

The Impact of Parenting Stress: A Meta-analysis of Studies Comparing the Experience of Parenting Stress in Parents of Children With and Without Autism Spectrum Disorder

E. K. Farran and A. Karmiloff-Smith: Neurodevelopmental Disorders Across the Lifespan: A Neuroconstructivist Approach

Are the Autism and Positive Schizotypy Spectra Diametrically Opposed in Empathizing and Systemizing?

A Parent-Mediated Intervention to Increase Responsive Parental Behaviors and Child Communication in Children with ASD: A Randomized Clinical Trial